Heart rhythm hope: weight loss drug trial targets common irregular heartbeat
NCT ID NCT06499857
Summary
This study is testing if a medication called semaglutide, which is approved for weight loss, can help people with both obesity and atrial fibrillation (AFib). Researchers want to see if losing weight with this drug can reduce how often AFib occurs and its severity when used alongside standard AFib treatments like medication or procedures. They are enrolling 200 adults who are overweight and have AFib to compare the drug against a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Arizona College of Medicine- Phoenix
NOT_YET_RECRUITINGPhoenix, Arizona, 85004, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.